DanDrit Biotech USA Inc. Announces new Therapeutic Research Strategy

June 12, 2017

New York, USA

DanDrit Biotech USA, Inc. ("DanDrit" or the "Company") is pleased to announce that on June 6, 2017, Mr. Rene Sindlev and Mr. Torben Bjørn Christensen, joined Dandrit's Board of Directors (the "Board") as part of a new strategy to expand the Company's focus beyond its ongoing clinical drug trials to develop new therapeutic programs to treat cancer and other serious diseases.

Read the full statement here.

Back to News